Lyophilised liposome-based formulations of alpha-tocopheryl succinate: preparation and physico-chemical characterisation

Kód výsledku v IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00027162%3A_____%2F10%3A%230000617" target="_blank" >RIV/00027162:_____/10:#0000617 - isvavai.cz</a>

Nalezeny alternativní kódy

RIV/86652036:_____/10:00349342

Výsledek na webu

—

DOI - Digital Object Identifier

—

Jazyk výsledku

angličtina

Název v původním jazyce

Lyophilised liposome-based formulations of alpha-tocopheryl succinate: preparation and physico-chemical characterisation

Popis výsledku v původním jazyce

alpha-Tocopheryl succinate (TOS) exerts selective toxicity to the cancer cells and anticancer activity in vivo. Yet, no suitable formulation of TOS for medical application has been reported. We developed and characterised a stable lyophilised liposome-based TOS formulation. TOS (15 mol%) was incorporated into large oligolamellar vesicles composed of soy phosphatidylcholine by the method of lipid film hydration followed by extrusion through polycarbonate filters. Stabilised liposomal formulation was prepared by lyophilisation in the presence of sucrose (molar ratio lipid/sucrose, 1:5). The size distribution of the liposomes (130-140 nm, polydispersity index 0.14) as well as the stable lipid and TOS contents were preserved during storage in the lyophilised form for at least 6 months. The data indicate good physical and chemical stability of the lyophilised preparation of TOS liposomes that can be used in clinical medicine.

Název v anglickém jazyce

Lyophilised liposome-based formulations of alpha-tocopheryl succinate: preparation and physico-chemical characterisation

Popis výsledku anglicky

alpha-Tocopheryl succinate (TOS) exerts selective toxicity to the cancer cells and anticancer activity in vivo. Yet, no suitable formulation of TOS for medical application has been reported. We developed and characterised a stable lyophilised liposome-based TOS formulation. TOS (15 mol%) was incorporated into large oligolamellar vesicles composed of soy phosphatidylcholine by the method of lipid film hydration followed by extrusion through polycarbonate filters. Stabilised liposomal formulation was prepared by lyophilisation in the presence of sucrose (molar ratio lipid/sucrose, 1:5). The size distribution of the liposomes (130-140 nm, polydispersity index 0.14) as well as the stable lipid and TOS contents were preserved during storage in the lyophilised form for at least 6 months. The data indicate good physical and chemical stability of the lyophilised preparation of TOS liposomes that can be used in clinical medicine.

Druh

J_x - Nezařazeno - Článek v odborném periodiku (Jimp, Jsc a Jost)

CEP obor

FR - Farmakologie a lékárnická chemie

OECD FORD obor

—

Projekt

<a href="/cs/project/KAN200520703" target="_blank" >KAN200520703: Použití ultrazvuku v nanomedicíně</a><br>

Návaznosti

P - Projekt vyzkumu a vyvoje financovany z verejnych zdroju (s odkazem do CEP)<br>Z - Vyzkumny zamer (s odkazem do CEZ)

Rok uplatnění

2010

Kód důvěrnosti údajů

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Název periodika

Journal of Pharmaceutical Sciences

ISSN

0022-3549

e-ISSN

—

Svazek periodika

99

Číslo periodika v rámci svazku

5

Stát vydavatele periodika

US - Spojené státy americké

Počet stran výsledku

12

Strana od-do

—

Kód UT WoS článku

000277132500020

EID výsledku v databázi Scopus

—